The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

The US FDA has approved Moderna's new COVID-19 vaccine, mNEXSPIKE, amidst emerging coronavirus variants. It is approved for adults 65 and older, and individuals aged 12-64 with underlying risk factors ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

THURSDAY, June 26, 2025 (HealthDay News) — Updated COVID-19 vaccines are keeping up with new coronavirus strains and remain ...

The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike, is part ...

The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine ...

GOP Rep. Marjorie Taylor Greene of Georgia, an outspoken COVID-19 vaccine critic, blasted the FDA's green lighting of the mNEXSPIKE as "Not MAHA at all!!!" in a tweet ...

The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spi ...

A new multi-state study led by the Centers for Disease Control and Prevention's (CDC) VISION Network—including Regenstrief ...

U.S. health officials have expanded warnings about a rare heart side effect associated with the two leading COVID-19 vaccines ...

The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 4 The FDA has approved Moderna’s next-generation COVID-19 vaccine for ...